Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Adrian Nordmark"'
Autor:
Ciara C O'Sullivan, Jun He, Jason Sinnwell, Vera J Suman, Krishna R Kalari, Peter T Vedell, Ann M Moyer, Xiaojia Tang, Kevin J Thompson, Abe Eyman Casey, Alvaro Moreno-Aspitia, Donald W Northfelt, Minetta C Liu, Tufia C Haddad, Saranya Chumsri, Brendan McMenomy, Prema Peethambaram, Kathryn J Ruddy, Karthik V Giridhar, Roberto A Leon-Ferre, Mattias Bergqvist, Adrian Nordmark, Richard M Weinshilboum, Liewei Wang, Matthew P Goetz
Publikováno v:
Cancer Research. 82:P5-13
Background: Cyclin dependent 4/6 kinase inhibitors (CDK4/6i) and endocrine therapy (ET) have improved progression-free survival (PFS) and overall survival in HR+ MBC, but progression of disease ultimately occurs. Apart from HR+ status, there are no c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e43090fc26b48da10fc87f2ae91ecc20
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-22
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-22
Autor:
Xiaojia Tang, Vera J. Suman, Ciara C O Sullivan, Kevin J. Thompson, Ann M. Moyer, Jason P. Sinnwell, Minetta C. Liu, Alvaro Moreno-Aspitia, Matthew P. Goetz, Kathryn J. Ruddy, Adrian Nordmark, Donald W. Northfelt, Liewei Wang, Tufia C. Haddad, Karthik V. Giridhar, Saranya Chumsri, Mattias Bergqvist, Roberto A. Leon-Ferre, Abraham Eyman Casey, Richard M. Weinshilboum, Peter T. Vedell, Krishna R. Kalari, Prema P. Peethambaram, Brendan P. McMenomy
Publikováno v:
Cancer Research. 81:PS5-24
Background: Cyclin dependent 4/6 kinase inhibitors (CDK4/6i) and endocrine therapy (ET) have improved progression-free survival (PFS) and overall survival in hormone-receptor (HR)-positive metastatic breast cancer (MBC), but progression of disease is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a90e760d0e7d70a809e0d9506e1ad19a
https://doi.org/10.1158/1538-7445.sabcs20-ps5-24
https://doi.org/10.1158/1538-7445.sabcs20-ps5-24